Apogem Capital Closes its Seventh and Largest Secondaries Fund at $1.43B Hard Cap

NEW YORK--(BUSINESS WIRE)--Apogem Capital (“Apogem”), a leading private markets investor, today announced the final close of Apogem Secondary Fund VII (“ASF VII” or the “Fund”) at its $1.43 billion hard cap. Including employee commitments, the Fund raised over $1.45 billion, exceeding its $1 billion target and more than doubling the size of its predecessor fund.

ASF VII pursues the firm’s established strategy of building a diversified portfolio of GP-led and LP secondary transactions across the North American middle market. Apogem has a longstanding focus on the segment and a well-established track record as a sole buyer in LP secondaries and as a lead or co-lead investor in GP-led transactions.

Mike Zeleniuch, Managing Director and Head of Liquidity Solutions at Apogem Capital, said:

“We are grateful for the continued support of our longstanding investors and pleased to welcome new institutional partners to ASF VII. Our Liquidity Solutions team has spent years structuring tailored capital solutions for middle market GPs and LPs. With ASF VII, we feel well-positioned to build on our demonstrated track record and to continue delivering innovative, high-quality solutions to our partners.”

The Fund received strong support from existing limited partners and attracted commitments from a diverse group of global institutional investors, including public and private pension plans, family offices, and RIAs. Apogem employees and its parent company, New York Life Insurance Company, also made meaningful commitments to the Fund.

Josh Niedner, Chief Executive Officer of Apogem Capital, added:

“The successful close of ASF VII marks an important milestone for our Liquidity Solutions business. As private equity markets continue to evolve, demand for customized liquidity solutions has grown significantly. We believe our focused middle market strategy, disciplined underwriting, and extensive network of private equity sponsor relationships position us well for the opportunities ahead.”

ASF VII benefits from Apogem’s scale and platform connectivity as a $44 billion private markets investment manager. The Fund draws on the firm’s deep relationships and deal flow generated across its broader private equity and credit programs.

About Apogem Capital

Apogem Capital is a leading private markets investor with 35 years of experience and expertise across private credit and private equity in North America. As of December 31, 2025, the firm manages approximately $44 billion in assets. Apogem provides a comprehensive suite of solutions, including direct lending, private equity funds and co-investments, GP-led transactions and LP secondaries, GP stakes, and private real assets.

With a team of over 250 professionals, including more than 120 investment professionals, Apogem combines deep domain expertise with the stability and long-term perspective of its parent company, New York Life Insurance Company. Apogem Capital is a wholly owned subsidiary of New York Life through New York Life Investment Management Holdings, LLC.

For more information, visit apogemcapital.com.